Skip to main content

Vivo Capital — Portfolio, Page 2

Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.

165
Companies
$12.4B
Total invested
$110.3M
Avg. check
22
Industries
Biotechnology 21Health Care 13Therapeutics 9Life Science 8Pharmaceutical 7Biopharma 6+16 more
Founder contacts

Verified emails & LinkedIn for founders across this portfolio.

jane@on●●●●●●●.com
linkedin.com/in/●●●●●●
Verified contacts, updated monthly
Get instant access →

Portfolio companies

Showing 2548 of 165
ORIC Pharmaceuticals
May 2025

ORIC Pharmaceuticals is a biopharmaceutical company that develops treatments that target the causes of therapeutic resistance.

Biopharma · South San Francisco$125.0M Post-IPO Equity
Icosavax
May 2023

Icosavax is focused on developing safe and effective vaccines against infectious diseases that address important unmet medical needs.

Biotechnology · Seattle$67.8M Post-IPO Equity
Whitehawk Therapeutics
May 2026

Whitehawk Therapeutics, a clinical-stage oncology therapeutics firm, applies cutting-edge technologies to well-established tumor biology.

Biopharma · Pacific Palisades$87.5M Post-IPO Equity
Provivi
April 2026

Provivi develops biopesticides for agriculture, commercial, household, and public health pest management.

Agriculture · Santa MonicaDebt Financing
Valneva
April 2026

Valneva focuses on the development and commercialization of prophylactic vaccines for infectious diseases.

Biotechnology · Saint-herblain$43.1M Post-IPO Equity
Bonum Therapeutics
April 2026

Bonum Therapeutics creates a technology platform to treat a wide range of diseases.

Biotechnology · Seattle$26.9M Venture - Series Unknown
Trevi Therapeutics
April 2026

Trevi Therapeutics is a clinical-stage biopharmaceutical company that develops drugs for treating uremic pruritus.

Biotechnology · Sandy Hook$173.0M Post-IPO Equity
Revolution Medicines
April 2026

Revolution Medicines is an innovative and dynamic organization of expert biologists, chemists, pharmacologists, clinical scientists.

Health Care · Redwood City$1.5B Post-IPO Equity
Ossium Health
April 2026

Ossium Health builds a bone marrow bank to treat blood cancers.

Biotechnology · San Francisco$15K Venture - Series Unknown
AN2 Therapeutics
March 2026

AN2 Therapeutics focuses on modern biomedical and drug development expertise to provide transformational medicines.

Biotechnology · Menlo Park$40.0M Post-IPO Equity
Zenas BioPharma
March 2026

Zenas BioPharma is a biopharmaceutical company that focuses on developing immune-based therapies for patients.

Biopharma · Waltham$100.0M Post-IPO Equity
OnKure Therapeutics
March 2026

OnKure is a clinical-stage biopharma company developing precision medicines targeting validated cancer drivers.

Biotechnology · Boulder$150.0M Post-IPO Equity
Surrozen
March 2025

Surrozen is a biopharmaceutical that focuses on unlocking the body’s regenerative power to treat injury and disease.

Biotechnology · South San Francisco$175.0M Post-IPO Equity
Candid Therapeutics
March 2026

Candid Therapeutics develops therapies for autoimmune diseases using antibody-based technologies that modulate immune system activity.

Biotechnology · San Diego$505.0M Undisclosed
Clasp Therapeutics
March 2024

Clasp Therapeutics offers to reach of immuno-oncology with novel precision medicines that enable the immune system.

Biotechnology · Cambridge$150.0M Series A
SAB Biotherapeutics
March 2026

SAB Biotherapeutics is a clinical-stage biopharmaceutical development company.

Biotechnology · Sioux Falls$85.0M Post-IPO Equity
Alto Neuroscience
March 2026

Alto Neuroscience is a clinical-stage biopharmaceutical company that creates precision medicines through its AI-driven biomarker platform.

Artificial Intelligence (AI) · Los Altos$120.0M Post-IPO Equity
Aerobiotix
March 2022

Aerobiotix is a privately held company specializing in the development and manufacture of proprietary environmental management devices.

Health Care · Miamisburg$10.0M Debt Financing
Unicycive Therapeutics
March 2024

Unicycive Therapeutics provides development programs that focus on treating kidney diseases with unmet medical needs.

Biotechnology · Los Altos$50.0M Post-IPO Equity
Tarsus Pharmaceuticals
March 2025

Tarsus Pharmaceuticals is a clinical-stage biopharmaceutical company that develops treatments for diseases with high unmet need.

Biopharma · Irvine$125.0M Post-IPO Equity
ASLAN Pharmaceuticals
March 2024

ASLAN Pharmaceuticals is an oncology-focused biotechnology company developing a portfolio of immuno-oncology agents and targeted therapies.

Biotechnology · Singapore$5.0M Post-IPO Equity
Arcutis Biotherapeutics
February 2024

Arcutis Biotherapeutics is a clinical-stage biopharmaceutical company focused on developing medical dermatology for unmet needs.

Biopharma · Westlake Village$150.0M Post-IPO Equity
COMPASS Pathways
February 2026

Compass Pathways is a mental health care company that focuses on developing therapies for treatment-resistant depression.

Biotechnology · Altrincham$200.0M Post-IPO Equity
Immunic Therapeutics
February 2026

Immunic is a biopharmaceutical company that develops a pipeline of selective oral immunology therapies.

Biotechnology · New York$400.0M Post-IPO Equity

Where Vivo Capital invests

Biotechnology21
Health Care13
Therapeutics9
Life Science8
Pharmaceutical7
Biopharma6

About Vivo Capital's portfolio

How many companies has Vivo Capital invested in?

Vivo Capital has invested in 165 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.

What industries does Vivo Capital invest in?

Vivo Capital's top investment sectors include Biotechnology, Health Care, Therapeutics, Life Science, Pharmaceutical. The firm invests across 22 different industry categories.

What is Vivo Capital's largest investment?

Among tracked funding rounds, Revolution Medicines received $1.5B in a Post-IPO Equity round. Vivo Capital's total known invested capital is $12.4B.

What is the average investment size for Vivo Capital?

Vivo Capital's average investment size is $110.3M across its portfolio of 165 companies.

What are Vivo Capital's most recent investments?

Recent Vivo Capital portfolio additions include ORIC Pharmaceuticals, Icosavax, Whitehawk Therapeutics, Provivi, Valneva. These companies were founded in 2020 or later.

Reach the founders behind these 165 companies
Verified emails and LinkedIn profiles, updated monthly.
Get instant access →